<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20771">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02836483</url>
  </required_header>
  <id_info>
    <org_study_id>LCB01-0371-15-2-01</org_study_id>
    <nct_id>NCT02836483</nct_id>
  </id_info>
  <brief_title>A Clinical Study of LCB01-0371</brief_title>
  <official_title>A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial to Evaluate the EBA, Safety and PK of Orally Administered LCB01-0371 in Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LegoChem Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LegoChem Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II
      Trial of LCB01-0371.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to explore antituberculosis of LCB01-0371 through the assess of the
      early bactericidal activity, safety of administration.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The extended early bactericidal activity (extended EBA) expressed as the change of log colony forming units of sputum from baseline at Day 15</measure>
    <time_frame>V2(Baseline), V9(Day 15)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The standard early bactericidal activity (standard EBA) expressed as the change of log colony forming units of sputum from baseline at Day 3</measure>
    <time_frame>V2(Baseline), V4(Day 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The extended early bactericidal activity (extended EBA) expressed as the change of log colony forming units of sputum from Day 2 at Day 15</measure>
    <time_frame>V4(Day 2), V9(Day 15)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The extended early bactericidal activity (extended EBA) expressed as the change of log colony forming units of sputum from Day 2 at Day 8</measure>
    <time_frame>V4(Day 2), V6(Day 8)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371 800mg, QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tubes 3~5Tablet, QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zyvox 300mg, BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 800mg, QD</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>LCB01-0371</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tubes 3~5Tablet, QD</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Tubes Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zyvox 300mg, BID</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Zyvox Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Korean who After listening to understand the details about the clinical trial,
             decided to join in the clinical study, and written consent

          2. The age of consent at the time of writing, only men and women under 50 years old over
             19 years old

          3. The First diagnosis of tuberculosis and have not received tuberculosis treatment for
             TB patients

        Exclusion Criteria:

          1. Known history of Rifampicin or Isoniazid resistance, and/or confirmed resistant by
             Xpert MTB RIF test result

          2. Serious TB for example tuberculous encephalomeningitis, It is impossible to
             participate in clinical trials

          3. Known History of nontuberculous mycobacteria positive

          4. It is impossible to participate in clinical trials except TB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>T.S Sim, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>T.S Sim, M.D., Ph.D</last_name>
    <phone>82-2-3010-3892</phone>
    <email>shimts@amc.seoul.kr</email>
  </overall_contact>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 18, 2016</lastchanged_date>
  <firstreceived_date>July 5, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Linezolid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
